HC Wainwright Cuts Keros Therapeutics (NASDAQ:KROS) Price Target to $40.00

Keros Therapeutics (NASDAQ:KROS) had its target price decreased by HC Wainwright from $47.00 to $40.00 in a research note released on Thursday morning,Benzinga reports. HC Wainwright currently has a buy rating on the stock.

Several other equities analysts also recently weighed in on the stock. Truist Financial decreased their price target on shares of Keros Therapeutics from $100.00 to $43.00 and set a “buy” rating on the stock in a research note on Monday, December 23rd. Guggenheim restated a “neutral” rating on shares of Keros Therapeutics in a research report on Friday, January 17th. BTIG Research cut shares of Keros Therapeutics from a “buy” rating to a “neutral” rating in a research report on Thursday, December 12th. Wells Fargo & Company raised their price objective on shares of Keros Therapeutics from $88.00 to $111.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 11th. Finally, TD Cowen cut shares of Keros Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, December 12th. Six investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $42.33.

Keros Therapeutics Trading Up 0.6 %

NASDAQ:KROS opened at $11.08 on Thursday. The company’s 50-day moving average price is $12.52 and its 200-day moving average price is $39.52. The company has a market cap of $448.82 million, a P/E ratio of -2.13 and a beta of 1.39. Keros Therapeutics has a twelve month low of $9.77 and a twelve month high of $73.00.

Keros Therapeutics (NASDAQ:KROS) last posted its quarterly earnings results on Wednesday, February 26th. The company reported ($1.14) earnings per share for the quarter, topping the consensus estimate of ($1.36) by $0.22. The firm had revenue of $3.04 million for the quarter, compared to the consensus estimate of $37.32 million. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. On average, analysts expect that Keros Therapeutics will post -4.74 earnings per share for the current year.

Institutional Investors Weigh In On Keros Therapeutics

A number of institutional investors have recently made changes to their positions in the stock. TFG Asset Management GP Ltd acquired a new stake in shares of Keros Therapeutics during the fourth quarter valued at about $1,630,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in shares of Keros Therapeutics by 27.4% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 64,416 shares of the company’s stock valued at $1,020,000 after acquiring an additional 13,864 shares during the last quarter. Twinbeech Capital LP grew its holdings in shares of Keros Therapeutics by 742.5% in the fourth quarter. Twinbeech Capital LP now owns 129,553 shares of the company’s stock valued at $2,051,000 after purchasing an additional 114,175 shares in the last quarter. Two Sigma Advisers LP grew its holdings in shares of Keros Therapeutics by 200.0% in the fourth quarter. Two Sigma Advisers LP now owns 20,700 shares of the company’s stock valued at $328,000 after purchasing an additional 13,800 shares in the last quarter. Finally, Two Sigma Investments LP grew its holdings in shares of Keros Therapeutics by 226.1% in the fourth quarter. Two Sigma Investments LP now owns 33,664 shares of the company’s stock valued at $533,000 after purchasing an additional 23,342 shares in the last quarter. 71.56% of the stock is currently owned by institutional investors and hedge funds.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.